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ABSTRACT
Objective: Familial hypercholesterolaemia (FH) affects
1 in 500 people in the UK population and is associated
with premature morbidity and mortality from coronary
heart disease. In 2008, National Institute for Health and
Care Excellence (NICE) recommended genetic testing
of potential FH index cases and cascade testing of their
relatives. Commissioners have been slow to respond
although there is strong evidence of cost and clinical
effectiveness. Our study quantifies the recent reduced
cost of providing a FH service using generic
atorvastatin and compares NICE costing estimates with
three suggested alternative models of care
(a specialist-led service, a dual model service where
general practitioners (GPs) can access specialist
advice, and a GP-led service).
Methods: Revision of existing 3 year costing template
provided by NICE for FH services, and prediction of
costs for running a programme over 10 years. Costs
were modelled for the first population-based FH service
in England which covers Southampton, Hampshire, Isle
of Wight and Portsmouth (SHIP). Population 1.95
million.
Results: With expiry of the Lipitor (Pfizer atorvastatin)
patent the cost of providing a 10-year FH service in
SHIP reduces by 42.5% (£4.88 million on patent vs
£2.80 million off patent). Further cost reductions are
possible as a result of the reduced cost of DNA testing,
more management in general practice, and lower
referral rates to specialists. For instance a dual-care
model with GP management of patients supported by
specialist advice when required, costs £1.89 million.
Conclusions: The three alternative models of care are
now <50% of the cost of the original estimates
undertaken by NICE.
INTRODUCTION
Familial hypercholesterolaemia (FH) affects
an estimated 1 in 500 people, but the vast
majority (85%) of affected people in the UK
are currently unaware of their status.1 Left
untreated 50% of men have coronary heart
disease by the time they are 50 years of age,
and at least 30% of women by the time they
are 60 years.2 In August 2008, National
Institute for Health and Care Excellence
(NICE) published a guideline for imple-
menting genetic testing of index case and
cascade testing of their relatives on the basis
of compelling evidence of clinical efﬁcacy
and cost-effectiveness.1 Current evidence
shows that if identiﬁed, patients with FH can
be offered high-dose statins, which extend
KEY MESSAGES
What is already known about this subject?
▸ Familial hypercholesterolaemia (FH) is an auto-
somal dominant condition affecting an estimated
1 in 500 people in the general population that
causes premature cardiovascular disease. Despite
the availability of genetic testing, 85% of people
with FH are undiagnosed. National Institute for
Health and Care Excellence (NICE) guidelines from
2008 describe a FH cascade testing and treatment
programme which is not only clinically effective in
diagnosing and treating FH, but is also cost-
effective (Incremental Cost-Effectiveness Ratio of
£2676 per quality-adjusted life-year (QALY) for
DNA testing and cholesterol testing vs cholesterol
testing only). Despite this guideline English
National Health Service (NHS) commissioners
have been reluctant to implement FH services,
apparently because of concerns over affordability.
What does this study add?
▸ This study reassesses the cost of a 10-year FH
service which identifies all undiagnosed FH car-
riers. By switching to treatment with generic
statins and managing more FH care through
general practice, the costs of FH services can be
more than halved, compared to NICE’s original
cost models.
How might this impact on clinical practice?
▸ Population-based FH services are less expensive
than previously thought. NHS commissioners
should now prioritise the implementation of FH
services. This would improve the care for people
with FH, reducing cardiovascular morbidity and
mortality.
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life by approximately 9 years.3 NICE recommends
cascade testing through families using a combination of
low-density lipoprotein (LDL) cholesterol and DNA
testing for patients with a deﬁnite or possible diagnosis
of FH at an incremental cost-effectiveness ratio of £2676
per quality-adjusted life-year (QALY) compared to LDL
cholesterol testing only.4 This cost per QALY is well
below NICE’s threshold for cost-effectiveness (£20 000
per QALY). FH cascade testing is, therefore, more cost
and clinically effective than most other models of care
provided by the NHS.
National FH services have been established in
Northern Ireland, Scotland and Wales.5 In England
there have been a number of successful research pro-
grammes in specialist centres6–8 and in 2013 there has
seen a renewed interest in implementation of an FH
service in the English NHS. The Cardiovascular Disease
Outcomes Strategy includes an ambition that ‘approxi-
mately 50%’ of English people with FH get diagnosed
and treated appropriately with potent statins9 and in
August 2013 NICE published FH quality standards.10 In
policy terms commissioning FH services improves the
allocative efﬁciency of the NHS (ie, the efﬁciency with
which the NHS allocates resources). Yet despite this
there were no population-based cascade testing pro-
grammes in England at the beginning of 2013. An
important reason for this paradoxical situation is that
Clinical Commissioning Groups (CCGs) consider new
FH services to be unaffordable given their existing
spending commitments and requirement to make
quality innovation productivity and prevention savings.
This study aimed to establish the total cost of provid-
ing a 10-year FH service that involves genetic testing of
index cases, cascade testing of relatives and annual
patient reviews, for three different models of care. We
used the NICE’s 2009 FH costing template11 to deter-
mine the affordability of a FH service for a population
of 1.95 million people in Southampton, Hampshire, Isle
of Wight and Portsmouth (SHIP). NICE estimated that
full implementation of their guideline would take 5–
10 years, but provided only a 3-year costing template,
partly because it was unclear what atorvastatin would
cost once its pharmaceutical patent owned by Pﬁzer
expired in November 2011. Our study estimates the cost
of a 10-year FH cascade testing programme using NICE’s
costs, and compares these to a revised lower cost service,
once atorvastatin was widely available across the UK as a
less expensive generic drug. We have also evaluated
whether costs can be further reduced, without com-
promising clinical quality, by comparing three models of
service delivery with varying amounts of support from
specialists and general practice.
METHODS
Full details of the methodology can be found in the
online supplementary technical appendix. NICE’s 2009
costing template11 calculated the costs of the ﬁrst 3 years
of a FH service. The costing template was extended to
cover the 10 years of a FH service which aims to identify
all FH carriers in the SHIP area. Lipid-lowering medica-
tion costs were updated to take account of off patent
atorvastatin. The costs of a 10-year FH service in SHIP
were calculated ﬁrst using NICE’s 2009 costing template
assumptions, but substituting the cost of on patent ator-
vastatin (£367 74 per annum with patients receiving
either a 40 or 80 mg dose) with generic simvastatin
(£60.36 per annum with patients receiving a 80 mg
dose) (N.B. Since 2011, because of the higher risk of
muscle damage with 80 mg/day this dose is not recom-
mended in clinical practice).
The NICE assumptions were then altered to compare
three possible models of delivery which aim to reduce
the costs of a FH service further. These models of deliv-
ery were considered with varying input from specialists
and GPs:
1. The ﬁrst model considered was a specialist-led
model. This model was similar to the NICE model
with the exception that a lower proportion of patients
would have annual reviews in secondary care.
2. The second model involved primary care taking
responsibility for the entire adult FH care pathway. In
this model a third fewer patients would be referred to
a FH specialist (locally this means a lipidologist) and
all patients would be reviewed annually by their GP.
3. The ﬁnal model was a ‘dual care’ model where
primary care would manage the majority of the FH
cascade testing pathway. In this ﬁnal model, GPs
would be able to refer patients to lipidologists if they
needed further advice about management, or to
genetic services, when advice on cascade testing was
needed because a genetic mutation had not been
identiﬁed.
The details of how the three delivery models differ are
shown in ﬁgure 1, table 2 and the online supplementary
technical appendix.
RESULTS
The costs of a 10-year programme
The 10-year model was run twice for SHIP, once with
atorvastatin costing £367 74 (40 or 80 mg in the NICE
model) per patient per annum and then with atorvasta-
tin at the 2009 cost of generic simvastatin 80 mg which
was £60.36 per patient per annum. (see table 1 and
ﬁgure 2). The gross cumulative cost of the FH service
was £5 527 750 with atorvastatin on patent or £3 534 750
over the 10-year programme with atorvastatin off patent.
The net cost of the FH service was £4 876 321 with ator-
vastatin on patent or £2 804 150 with atorvastatin off
patent incorporating saved costs from avoided cardiac
events (see table 1). With generic atorvastatin the FH
service becomes 42.5% less expensive.
Between year 1 and year 7, 3547 people participate in
the FH service of which 470 (13.3%) are index cases
and 3077 (86.7%) are relatives. The 10-year costings
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demonstrate that the cost of a FH service does not rise
year on year as might be suggested by NICE’s 3-year
costing template. There were predicted peaks in cost
during year 3 (£496 000 with atorvastatin on patent and
£338 000 off patent) and in year 7 (£615 000 with ator-
vastatin on patent and £340 000 off patent). Our model-
ling predicts that it takes 8 years for the investment in a
FH service to be fully realised in terms of avoided
cardiac events. In year 1 each cardiac event avoided cost
£116 000 with atorvastatin on patent or £95 000 off
patent. From year 8 onwards each cardiac event avoided
cost £38 000 with atorvastatin on patent or £18 000 off
patent.
Importantly, the cost of drug therapy was the most
expensive component of the programme, £3.74 million
(67.7%) with atorvastatin on patent or £1.75 million
(49.5%) off patent. This was followed by cascade testing
(£910 000 in both models), annual patient review meet-
ings (£742 000 in both models) and specialist referrals
(£135 000 in both models). In the off patent model,
cascade testing accounts for 25.7% of costs, annual
reviews 21% of costs and specialist referrals 3.8%. After
cascade testing ﬁnishes in year 7, the major expense of a
FH service is the annual review. The avoidance of
cardiac events saved £651 000 over a decade, reducing
the cost of the programme by 11.8% with atorvastatin on
patent or 20.7% with atorvastatin off patent.
Comparing the costs of the three models of delivery
Spurred on by the widespread availability of generic and
less expensive atorvastatin prescribing, clinicians and
managers in SHIP further modiﬁed local costs in the
NICE template. Three alternative models of delivery
were devised (specialist led, dual care and GP led) to
determine whether a FH service could be made less
expensive and even more affordable.
Regardless of the three models of delivery for adults,
all paediatric referrals would continue to follow NICE’s
Figure 1 Care pathway for suspected patients with familial hypercholesterolaemia, comparing three alternative models of
delivery.
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recommended care pathway involving specialist referral.
The following changes to the default assumptions in the
NICE costing template for adults (see table 2).
With the exception of a higher local cost for DNA
testing for an identiﬁed mutation (£75 vs NICE’s £50)
all the changes made to the NICE costings reduced the
cost of the SHIP programme. The reduction in costs for
simvastatin 80 mg (£60.36 to £29.33 per annum) and
atorvastatin (£367.74 per annum to £25.16 for 40 mg or
£45.49 for 80 mg) have dramatically reduced the cost of
drug treatment. With generic atorvastatin available it is
now unjustiﬁable that 40% of patients with FH should
receive rosuvastatin (28 days of 20 mg rosuvastatin cur-
rently costs £26.02 in the UK, compared with 20 mg ator-
vastatin costing £1.71, but without additional proven
clinical beneﬁt). In all models of delivery it is assumed
that the majority will be switched to atorvastatin. The
three delivery models diverge from NICE by starting
with a very high percentage of annual reviews being
delivered in general practice (in the case of the GP-led
model 100%). In the dual-care and GP-led models a
third fewer patients (20% vs 30%) are referred to a FH
specialist, though in all models it is assumed that 10% of
patients will still be referred to a cardiologist. It was also
decided that a SHIP programme would not have the
same scope to identify relatives as a national pro-
gramme. This followed a 2007 national audit8 which
showed that a third (34%) of relatives lived outside lipid
clinic catchment areas. As SHIP is larger than a lipid
clinic catchment area, but relatively small compared to
England, it was assumed that a quarter (25%) fewer ﬁrst-
degree, second-degree and third-degree relatives would
be identiﬁed.
Local modiﬁcations to the NICE costing template
meant that all three models of delivery were more
affordable than the original NICE model (see table 3
and ﬁgure 3).
As the SHIP FH service is stand alone, as opposed to
being part of a national FH service, fewer relatives par-
ticipate in cascade testing as a proportion will live out of
area. In the SHIP models 2307 relatives participate com-
pared to 3077 in the NICE model, a 25% reduction.
With fewer FH carriers identiﬁed there are fewer cardio-
vascular events avoided. As a result it is anticipated that
over 10 years 25 revascularisations will be avoided com-
pared to 37 as part of a national programme (a 32.4%
reduction) and 51 myocardial infarctions avoided com-
pared to 68 as part of a national programme (a 25%
reduction).
The local modiﬁcations to the NICE costing template
reduce the cost of a FH service substantially, but not to
the same extent as the introduction of generic atorvasta-
tin. Generic atorvastatin reduces the cost of a 10-year
service by 42.5% (£4 876 321 to £2 804 150). Compared
to NICE costing estimates with generic atorvastatin: the
specialist led model reduces 10-year costs by 27.2%
(£2 804 150 to £2 041 000); the dual-care model by
32.5% (£2 804 150 to £1 894 000); and the GP-led model
by 35.8%% (£2 804 150 to £1 801 000). The NICE cost-
ings with atorvastatin on patent are 2.4-fold greater
than the specialist-led model, 2.6-fold greater than the
dual-care model and 2.7-fold greater than the GP-led
model.
The variation in costs between local models result
mainly from number of patients referred to specialists in
secondary care (see table 4). This affects the costs of
cascade testing depending on whether it is initiated by a
lipidologist, specialist referrals (the proportion of
patients managed in general practice) and annual
review meetings (whether these are carried out in
general practice at £36.28 each or by a specialist at
£97.87). This explains why the costs of models tend to
converge once cascade testing is completed in year 7
when there are fewer opportunities for patients to see
specialists. The difference in cost between the most
expensive option, specialist led, and the cheapest
option, GP led, is a relatively modest £240 000 over a
10-year programme.
Currently the cost of DNA testing in SHIP is £250 for
index cases and £70 for previously identiﬁed mutations.
With recent developments in sequencing platforms the
cost of hardware has fallen and potential sequencing
throughput has increased. The costs of DNA testing are
likely to fall considerably over the next 2 years. The
expectation is that the costs of DNA testing will reduce
to £200 for index cases and £50 for their relatives rela-
tively quickly. If this occurs the cost of the year 3 FH
service would be £221 800 (a further 7.6% reduction in
cost) for the specialist-led model, £194 000 (a 6.1%
reduction) for the dual-care model or £180 000 (a 9.3%
reduction) for the GP-led model. Further reductions in
the cost of DNA testing are possible at a later stage of
the programme.
DISCUSSION
Principal findings
Our results show that each of these models of service
delivery can be provided for less than half the cost of
the original estimates undertaken by NICE. Expiry of
the Pﬁzer patent on proprietary Lipitor restricting use
of atorvastatin in November 2011, and options to
modify delivery models have made providing a FH
service much more affordable than suggested by the
NICE 2009 costing template. Once the savings from
avoided cardiac events are taken into account, a
10-year programme for a population of 1.95 million
people costs £2.80 million, 42.5% less than the £4.88
million it would have cost if atorvastatin remained on
patent. Over 10 years the FH service with atorvastatin
off patent has drug therapy costs of £1.75 million
(49.5% of programme costs and still the most costly
component of the programme). Cascade testing costs
£910 000 (25.7% of the programme), annual reviews
costs of £742 000 (21%) and specialist review costs of
£135 000 (3.8%). There are £651 000 savings from
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Table 1 Costs and clinical benefits of a 10-year FH service in the SHIP area. Costs with atorvastatin on and off patent compared in £’000s
Years since start of programme 1 2 3 4 5 6 7 8 9 10 Cumulative Cumulative (%)
NICE cascade testing programme. Atorvastatin on patent
Numbers tested
Number tested—index cases 94 94 94 47 47 47 47 0 0 0 470 13.3
Number tested—relatives 615 615 615 308 308 308 308 0 0 0 3077 86.7
Total number tested 709 709 709 355 355 355 355 0 0 0 3547 100.0
Costs (in £’000s)
Drug therapy £98 £197 £296 £345 £394 £443 £492 £492 £492 £492 £3741 67.7
Cascade testing £182 £182 £182 £91 £91 £91 £91 £0 £0 £0 £910 16.5
Annual review meetings £0 £23 £46 £69 £81 £92 £104 £109 £109 £109 £742 13.4
Specialist referrals £27 £27 £27 £14 £14 £14 £14 £0 £0 £0 £135 2.4
Value of coronary events avoided −£17 −£33 −£55 −£60 −£68 −£77 −£85 −£85 −£85 −£85 −£651 −11.8
Total recurrent costs per annum. £290 £396 £496 £459 £511 £563 £615 £516 £516 £516 £4876
Total programme costs excluding clinical savings £5528 100.0
NICE cascade testing programme. Atorvastatin off patent
Numbers tested
Number tested—index cases 94 94 94 47 47 47 47 0 0 0 470 13.3
Number tested—relatives 615 615 615 308 308 308 308 0 0 0 3077 86.7
Total number tested 709 709 709 355 355 355 355 0 0 0 3547 100.0
Costs (in £’000s)
Drug therapy £46 £92 £138 £161 £184 £207 £230 £230 £230 £230 £1748 49.5
Cascade testing £182 £182 £182 £91 £91 £91 £91 £0 £0 £0 £910 25.7
Annual review meetings £0 £23 £46 £69 £81 £92 £104 £109 £109 £109 £742 21.0
Specialist referrals £27 £27 £27 £14 £14 £14 £14 £0 £0 £0 £135 3.8
Value of coronary events avoided −£17 −£33 −£55 −£60 −£68 −£77 −£85 −£85 −£85 −£85 −£649 −20.7
Total recurrent costs per annum £238 £291 £338 £266 £291 £316 £340 £242 £242 £242 £2804
Total programme costs excluding clinical savings £3535 100.0
Benefits
Revascularisations avoided per annum 1 1 3 3 4 4 5 5 5 5 35 33.7
MIs avoided per annum 2 3 5 6 7 8 9 9 9 9 68 66.3
Total (cardiac events avoided) 3 5 8 10 11 12 14 14 14 14 103 100.0
Cost per cardiac event avoided
Atorvastatin on patent £116 £86 £60 £48 £47 £46 £45 £38 £38 £38
Atorvastatin off patent £95 £63 £41 £28 £27 £26 £25 £18 £18 £18
Costs are rounded to the nearest £1000 and number of events avoided are rounded to the nearest whole number. This results in the cumulative totals not always being the exact sum of the
component numbers in that sum.
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Table 2 SHIP modifications to the NICE template
Template
component Item NICE Local modifications Reason for modification
Drug treatment Proportions receiving
statins
20% simvastatin, 40%
atorvastatin, 40%
rosuvastatin
20% simvastatin, 72% atorvastatin, 8%
rosuvastatin
Atorvastatin has lost exclusivity. Medicines
management discourages prescribing of
rosuvastatin
Cost of statins Simvastatin 80 mg £60.36
per annum
Simvastatin 80 mg £29.33 per annum April 2013 drug tariff
Atorvastatin 40 mg or 80 mg
£367.74 per annum
Atorvastatin £35.33 per annum (average of
£25.16 for 40 mg and £45.49 for 80 mg)
April 2013 drug tariff
Cascade testing Average number of
relatives identified
4 first degree, 8 second
degree, 12 third degree
3 first degree, 6 second degree, 9 third
degree
SHIP programme will not benefit from relative
identification in rest of England
DNA test to identify
indivudal mutation
£400 £250 Cost of sequencing has fallen
DNA test for previously
identified mutation
£50 £70 Local cost higher
Annual review
meeting
Proportion followed up
in general practice
28% in year 1, 52% in year
2, 64% in year 3
80% 3 in specialist and dual models.
100% in GP-led model
No local research programme established so
programme can start with most/all follow-up by
GPs
Specialist
referrals
Proportion referred to
FH specialist
30% 30% in specialist model, 20% in dual-and
GP-led model
With exception of specialist model there is great
emphasis on care in general practice
Cost of referreal to FH
specialist
£355.47 £322.00 Local tariff
FH, Familial hypercholesterolaemia; GP, general practitioner; NICE, National Institute for Health and Care Excellence; SHIP, Southampton, Hampshire, Isle of Wight and Portsmouth.
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avoided cardiac events, saving 20.7% of the costs of
the programme. Three models of delivery devised in
SHIP (population 1.95 million), demonstrate that
further savings are possible. Costs could also be
reduced by switching patients from Astra Zeneca
owned Crestor (rosuvastatin) which is protected by a
substance patent until 8 January 2016, to genetic
atorvastatin, utilising technologically improved cheaper
DNA testing, holding more annual reviews in general
practice and by better management in primary care.
Compared to NICE costing with atorvastatin off
patent, the specialist-led model is 27.2% less expen-
sive, the dual care model is 32.5% less expensive and
the GP-led model is 35.8% less expensive. Reductions
Figure 2 Evolution over 10 years of the costs and benefits of a familial hypercholesterolaemia service in Southampton,
Hampshire, Isle of Wight and Portsmouth area with atorvastatin on and off patent.
Table 3 Comparison of original NICE costings for SHIP with modified costings for the three alternative models of delivery in
£’000s
Years since start of programme 1 2 3 4 5 6 7 8 9 10 Cumulative
Numbers tested NICE model
Number tested—index cases 94 94 94 47 47 47 47 0 0 0 470
Number tested—relatives 615 615 615 308 308 308 308 0 0 0 3077
Total number tested 709 709 709 355 355 355 355 0 0 0 3547
Costs (in £000’s)
NICE cost, atorvastatin on patent £290 £396 £496 £459 £511 £563 £615 £516 £516 £516 £4876
NICE cost, atorvastatin off patent £238 £291 £338 £266 £291 £316 £340 £242 £242 £242 £2804
Numbers tested SHIP Models
Number tested—index cases 94 94 94 47 47 47 47 0 0 0 470
Number tested—relatives 461 461 461 231 231 231 231 0 0 0 2307
Total number tested 555 555 555 278 278 278 278 0 0 0 2777
Costs (in £000’s)
Specialist led £170 £203 £240 £195 £213 £232 £250 £179 £179 £179 £2041
Dual-care model £137 £170 £207 £196 £197 £215 £234 £179 £179 £179 £1894
GP led £131 £162 £198 £187 £187 £205 £222 £170 £170 £170 £1801
GP, general practitioner; NICE, National Institute for Health and Care Excellence; SHIP, Southampton, Hampshire, Isle of Wight and
Portsmouth.
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in the cost of DNA testing over the next 2 years are
likely to make FH services even more affordable.
Strengths and limitations of study
Policy makers, clinicians and clinical commissioners are
already convinced that FH cascade testing is both highly
clinically effective and cost-effective. However, a strength
of our study is that it addresses a key, pragmatic aspect of
commissioning decisions that is not usually addressed in
economic evaluations of FH services: that is, service costs.
FH services are more affordable now than originally envi-
saged by NICE but to be more comprehensive our study
should have compared the affordability of FH services
with other services in the cardiovascular and cardiology
specialty. To have carried out this would have enabled
commissioners to prioritise more easily and this should
be an area of further research. Having modiﬁed the
original NICE costing model (table 2) it was not possible
to calculate QALY gains for the SHIP models compared
to NICE’s cost-effectiveness analysis. Despite the lack of
revised incremental cost-effectiveness ratios this study’s
considerable reduction in delivery costs between the
NICE and SHIP delivery models implies an improvement
in the cost-effectiveness. Another limitation, is that our
study does not include a sensitivity analysis which is a
concern when comparing costs of three alternative
models of delivery. Furthermore, a number of the
assumptions used in our study can be questioned.
However, that said, by extending NICE’s helpful 3-year
costing template to 10 years, commissioners can estimate
the full cost of a more complete programme. This evolu-
tion of costs is easier to estimate now that atorvastatin is
off patent, but it necessitates more assumptions than
NICE’s original model. In particular the pattern of index
Figure 3 Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire,
Isle of Wight and Portsmouth area: National Institute for Health and Care Excellence with atorvastatin off patent compared to
three alternative models of delivery.
Table 4 Comparison of cost components of alternative delivery models over 10 year (years in £’000s)
Costs (in £’000s) Specialist led Dual-care model GP led
Cost component Cost
Percentage
of cost Cost
Percentage
of cost Cost
Percentage
of cost
Cascade testing £620 25.4 £500 21.7 £470 22.4
Drug therapy £1055 43.2 £1055 45.9 £1055 50.3
Specialist referrals £85 3.5 £60 2.6 £60 2.9
Annual review meetings £685 28.0 £685 29.8 £515 24.5
Value of coronary events
avoided
−£290 −11.9 −
£290
−12.6 −£290 −13.8
Total recurrent costs per annum £2155 88.1 £2010 87.4 £1809 86.2
Total programme costs excluding
clinical savings
£2445 100.0 £2300 100.0 £2100 100.0
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case DNA testing is assumed to cover 20% of index cases
in years 1–3 and 10% in years 4–7. This estimate may not
be truly accurate. Locally lipid clinics have lists of sus-
pected patients with FH which have led to an initial rush
of DNA testing. It is possible that GP practices will not
refer patients into the new service to the extent that was
anticipated. This study has highlighted the potential for
further reductions in DNA testing costs. In fact some
costs may increase, but these have not been factored into
the analysis, for instance the cost of specialist appoint-
ments or new generation lipid lowering drugs.12
Problematically for commissioners, the assumptions in
the model are difﬁcult to evaluate retrospectively.
Commissioners will not beneﬁt from being able to view a
FH budget line. In practice most activity will be subsumed
into larger budgets, for instance Quality and Outcomes
Framework, phlebotomy and genetic testing.
Commissioners are not in the position to agree funding
for a 10-year programme, but rather fund on an annual
basis. If funding were stopped prematurely, it is reason-
able to anticipate there would be fewer avoided cardiac
events.
The three alternative delivery models offer creative
ways for the NHS to provide FH services at a lower cost
than the original NICE model. The models of service
delivery suggest that further savings are possible, above
and beyond, the use of less expensive generic atorvasta-
tin. We suggest the ﬁndings of our study are highly trans-
ferrable to other parts of England, as medication costs
are the same and other cost are likely to be similar. The
adjustments made to the NICE model in SHIP are listed
in table 2 but can be further reﬁned depending on local
circumstances. Within SHIP, there was considerable
debate about the extent to which the alternative models
were compliant with NICE quality standards, particularly
access to specialists. It was felt that the GP-led model pro-
vided patients with insufﬁcient support, and conse-
quently even though that model was the cheapest option,
it was rejected by CCGs. To compensate for decreased
access to lipidologists, geneticists and cardiologists, it has
been necessary to create FH coordinator posts, the full
costs (an experienced nurse) of which are not captured
by the nursing time allocated in the original NICE model
or this study. The FH coordinator has to set up the new
service, train GPs, assess the appropriateness of referrals,
liaise with specialists, travel between clinics and partici-
pate in continued professional development. Locally it is
thought that one FH coordinator post is needed per 1
million of the population. Further details about the SHIP
FH service are presented in box 1.
Implications of the study
Local modiﬁcations to the NICE FH care pathway have
implications for clinical effectiveness. The average
number of relatives identiﬁed through index cases had
Box 1 Southampton, Hampshire, Isle of Wight and
Portsmouth (SHIP) Wessex Familial Hypercholesterolaemia
Cascade Testing Service
The SHIP Wessex Familial Hypercholesterolaemia Cascade Testing
Service is overseen by a steering committee comprising of:
A Chair and representatives from: Commissioners from the
eight Community Commissioning Groups within SHIP (including
clinicians involved in cardiovascular risk reduction), Heart UK,
lipidologists from centres around the region managing patients
with FH, public health clinicians involved in cardiovascular health,
genetics counselling service involved in counselling of probands
and relatives.
▸ Patients are informed about the Wessex FH Cascade Testing
Service in clinic by either the lipidologist or general practi-
tioner (GP) using the locally modified Simon Broome FH diag-
nostic criteria (see box 2)
▸ Patient’s details sent to the Wessex Genetic counselling
service
▸ Letter of introduction is sent by the Wessex Genetic counselling
service to patient informing them of their referral to the Wessex
FH Cascade Testing Service. Initial contact with the service is
made by letter to acknowledge referral and to offer an appoint-
ment to meet with a genetic counsellor who arranges genetic
testing after discussion with the patient (proband).
▸ There are two methods for contacting relatives ‘ Direct’ or
‘Family contact’. These options are discussed with the patient
(proband) in their clinic appointment.
▸ A summary letter following each clinic appointment is sent to
the patient (proband) and all relatives with agreed actions,
and is copied to GP and/or referring clinican.
– Direct contact: involves the patient (proband) providing the
healthcare professionals with the names and addresses of their
relatives and the patient taking responsibility for contact.
– Family contact: involves the healthcare professional provid-
ing a ‘to whom it may concern letter’ to support the patient
(proband) in this process.
N.B. A mix of approaches is sometimes needed within families
and the best option is discussed on an individual patient basis.
Telephone contact is only be made with prior agreement from
patients (probands) and their families.
The Wessex FH Cascade Testing Service is using the FH-specific
PASS Clinical software (licences supported for 3 years by Astra
Zeneca). (PASS Clinical software has been successfully used in
several other FH screening programmes before, including Wales and
The Netherlands. HEART UK supports the use of PASS for FH
cascade testing in their report, ‘Saving Lives, Saving Families’).
Regular FH clinics started in October 2013. SHIP’s first FH special-
ist nurse left in October after only 4 months in post. From April 2014
three new FH specialist nurses/genetic counsellors, two of which are
part funded by the British Heart Foundation, should join the service
allowing a large increase in service capacity. This will enable the
service to be launched formally in general practice. Since the soft
launch of the service referrals into the FH service have increased
from one from a lipidologist in June 2013 to 52 in December 2013, 4
(7.7%) of which were from GPs and the rest from lipidologists.
Separate paediatric clinics have identified 30 FH carriers up to
December 2013. Numbers of referrals will continue to grow as a
result of cascade testing.
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to be reduced as a SHIP programme would not be
embedded in a national programme. The expectation is
that referrals to FH specialists are restricted in the dual-
care and GP-led models. GPs have concerns that the
new FH services could increase referrals to lipidologists.
To limit this risk locally, the FH coordinator will assess
the appropriateness of referrals into the new service and
discuss with lipidologists where necessary. Fewer annual
reviews in secondary care for all the SHIP models of
delivery reduce access to specialists further and the
amount of access to specialists is responsible for the
main differences in costs between the models. As NICE
makes clear in its costing report, GP costs relating to FH
are hidden to commissioners, but this service places a
small extra workload on busy local GPs.
Favourable costings were not perhaps the only factor
that persuaded GP commissioners in SHIP to invest in
FH services, though they did help. From 2008 when
NICE published its FH guidance, local champions from
general practice, public health, lipidology, genetics and
management have pushed for a FH service. Many
papers, meetings, presentations and false starts followed.
It was difﬁcult to get agreement across the four Primary
Care Trust (PCTs) covering our region, and following
the Health and Social Care Act 2012, agreement had to
be reached across eight local CCGs. However, after
several meetings lead GP commissioners were persuaded
that FH was an opportunity for CCGs to commission a
novel service for SHIP and once one CCG had agreed in
our region the precedent was set for all to follow.
Locally it was decided to implement the dual-care
model, even though this was not the least expensive, but
because it was felt necessary that this would provide
good use of local specialist expertise in FH manage-
ment. Once funding was agreed a whole new set of logis-
tic challenges emerged which are being met as
described in box 1.
Conclusions
Our modelling estimates show that the three presented
alternative models of care are now <50% of the cost of
the original estimates undertaken by NICE. Our work
provides a framework for NICE to consider reissuing its
costing template for implementation of an FH service.
By using the latest statin costs, by reducing the propor-
tion of patients prescribed more expensive
proprietary-owned rosuvastatin (Crestor), and by man-
aging more patients with FH in primary care, providing
an FH service is now much more affordable than pre-
dicted by NICE in 2008.
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Box 2 Locally modified Simon Broome FH diagnostic
criteria
Refer for cascade genetic testing if the following criteria are
present:
Possible FH
Total LDL >5.5 mmol/L in adult AND a triglyceride concentration
less than 4.0 mmol/L (measurements either pretreatment or
highest on treatment)
PLUS ONE OF THE FOLLOWING:
(1) Family history of myocardial infarction before age 50 in
second-degree relative or before age 60 in first-degree relative
(2) Family history of raised total cholesterol concentration above
8.0 mmol/L in first-degree or second-degree relative
Definite FH
The above criteria plus Tendon xanthomata (or evidence of these
in first-degree or second-degree relatives)
And/or DNA-based evidence of an low-density lipoprotein (LDL)
receptor mutation, familiar receptor defective apo-B100, or a
PCSK 9 mutation in patient or first-degree or second-degree
relative.
Note: Consider the diagnosis if LDL cholesterol substantially ele-
vated (ie, >6.0 mmol/L) even in the absence of a personal or
family history of coronary disease.
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